{"id":"lisaftoclax-btk-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Lisaftoclax inhibits BCL-2, an anti-apoptotic protein that allows cancer cells to evade programmed cell death. The BTK inhibitor component blocks Bruton's tyrosine kinase, a key signaling molecule in B-cell receptor pathways that promotes cell survival and proliferation. Together, these agents synergistically induce apoptosis in hematologic malignancies, particularly those dependent on both BCL-2 and BTK signaling.","oneSentence":"Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:08.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Other B-cell malignancies"}]},"trialDetails":[{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT06104566","phase":"PHASE3","title":"Global Trial in APG2575 for Patients With CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-12-20","conditions":"CLL/SLL","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"lisaftoclax +BTK inhibitor","genericName":"lisaftoclax +BTK inhibitor","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Other B-cell malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}